Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Using Tumor Explants for Imaging Mass Spectrometry Visualization of Unlabeled Peptides and Small Molecules.

David BP, Dubrovskyi O, Speltz TE, Wolff JJ, Frasor J, Sanchez LM, Moore TW.

ACS Med Chem Lett. 2018 May 17;9(7):768-772. doi: 10.1021/acsmedchemlett.8b00091. eCollection 2018 Jul 12.

PMID:
30034616
2.

Histone deacetylase inhibitor-based chromatin precipitation for identification of targeted genomic loci.

Hanigan TW, Danes JM, Taha TY, Frasor J, Petukhov PA.

J Biol Methods. 2018;5(1). pii: e88. doi: 10.14440/jbm.2018.216.

3.

A Cell-Permeable Stapled Peptide Inhibitor of the Estrogen Receptor/Coactivator Interaction.

Speltz TE, Danes JM, Stender JD, Frasor J, Moore TW.

ACS Chem Biol. 2018 Mar 16;13(3):676-684. doi: 10.1021/acschembio.7b01016. Epub 2018 Jan 24.

PMID:
29309722
4.

Coactivation of Estrogen Receptor and IKKβ Induces a Dormant Metastatic Phenotype in ER-Positive Breast Cancer.

El-Shennawy L, Dubrovskyi O, Kastrati I, Danes JM, Zhang Y, Whiteley HE, Creighton CJ, Frasor J.

Cancer Res. 2018 Feb 15;78(4):974-984. doi: 10.1158/0008-5472.CAN-17-1686. Epub 2017 Dec 11.

PMID:
29229606
5.

A Protective Role for Triacylglycerols during Apoptosis.

Li N, Sancak Y, Frasor J, Atilla-Gokcumen GE.

Biochemistry. 2018 Jan 9;57(1):72-80. doi: 10.1021/acs.biochem.7b00975. Epub 2017 Dec 13.

PMID:
29188717
6.

Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Amine-based Histone Deacetylase Inhibitors.

Abdelkarim H, Neelarapu R, Madriaga A, Vaidya AS, Kastrati I, Karumudi B, Wang YT, Taha TY, Thatcher GRJ, Frasor J, Petukhov PA.

ChemMedChem. 2017 Dec 19;12(24):2030-2043. doi: 10.1002/cmdc.201700449. Epub 2017 Nov 30.

PMID:
29080240
7.

Scaffold dependent histone deacetylase (HDAC) inhibitor induced re-equilibration of the subcellular localization and post-translational modification state of class I HDACs.

Hanigan TW, Taha TY, Aboukhatwa SM, Frasor J, Petukhov PA.

PLoS One. 2017 Oct 18;12(10):e0186620. doi: 10.1371/journal.pone.0186620. eCollection 2017.

8.

Divergent JNK Phosphorylation of HDAC3 in Triple-Negative Breast Cancer Cells Determines HDAC Inhibitor Binding and Selectivity.

Hanigan TW, Aboukhatwa SM, Taha TY, Frasor J, Petukhov PA.

Cell Chem Biol. 2017 Nov 16;24(11):1356-1367.e8. doi: 10.1016/j.chembiol.2017.08.015. Epub 2017 Sep 21.

PMID:
28943357
9.

Corrigendum: Full antagonism of the estrogen receptor without a prototypical ligand side chain.

Srinivasan S, Nwachukwu JC, Bruno NE, Dharmarajan V, Goswami D, Kastrati I, Novick S, Nowak J, Cavett V, Zhou HB, Boonmuen N, Zhao Y, Min J, Frasor J, Katzenellenbogen BS, Griffin PR, Katzenellenbogen JA, Nettles KW.

Nat Chem Biol. 2017 May 17;13(6):691. doi: 10.1038/nchembio0617-691c. No abstract available.

PMID:
28514424
10.

Erratum: Full antagonism of the estrogen receptor without a prototypical ligand side chain.

Srinivasan S, Nwachukwu JC, Bruno NE, Dharmarajan V, Goswami D, Kastrati I, Novick S, Nowak J, Cavett V, Zhou HB, Boonmuen N, Zhao Y, Min J, Frasor J, Katzenellenbogen BS, Griffin PR, Katzenellenbogen JA, Nettles KW.

Nat Chem Biol. 2017 May 17;13(6):691. doi: 10.1038/nchembio0617-691b. No abstract available.

PMID:
28514419
11.

A Novel Strategy to Co-target Estrogen Receptor and Nuclear Factor κB Pathways with Hybrid Drugs for Breast Cancer Therapy.

Kastrati I, Siklos MI, Brovkovych SD, Thatcher GRJ, Frasor J.

Horm Cancer. 2017 Jun;8(3):135-142. doi: 10.1007/s12672-017-0294-5. Epub 2017 Apr 10.

12.

Structural and Molecular Mechanisms of Cytokine-Mediated Endocrine Resistance in Human Breast Cancer Cells.

Stender JD, Nwachukwu JC, Kastrati I, Kim Y, Strid T, Yakir M, Srinivasan S, Nowak J, Izard T, Rangarajan ES, Carlson KE, Katzenellenbogen JA, Yao XQ, Grant BJ, Leong HS, Lin CY, Frasor J, Nettles KW, Glass CK.

Mol Cell. 2017 Mar 16;65(6):1122-1135.e5. doi: 10.1016/j.molcel.2017.02.008.

13.

Racial disparity in survival from estrogen and progesterone receptor-positive breast cancer: implications for reducing breast cancer mortality disparities.

Rauscher GH, Silva A, Pauls H, Frasor J, Bonini MG, Hoskins K.

Breast Cancer Res Treat. 2017 Jun;163(2):321-330. doi: 10.1007/s10549-017-4166-z. Epub 2017 Mar 1.

14.

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells.

Kastrati I, Delgado-Rivera L, Georgieva G, Thatcher GR, Frasor J.

J Vis Exp. 2017 Jan 18;(119). doi: 10.3791/54798.

15.

Full antagonism of the estrogen receptor without a prototypical ligand side chain.

Srinivasan S, Nwachukwu JC, Bruno NE, Dharmarajan V, Goswami D, Kastrati I, Novick S, Nowak J, Cavett V, Zhou HB, Boonmuen N, Zhao Y, Min J, Frasor J, Katzenellenbogen BS, Griffin PR, Katzenellenbogen JA, Nettles KW.

Nat Chem Biol. 2017 Jan;13(1):111-118. doi: 10.1038/nchembio.2236. Epub 2016 Nov 21. Erratum in: Nat Chem Biol. 2017 May 17;13(6):691. Nat Chem Biol. 2017 May 17;13(6):691.

16.

Correlative Analysis of miRNA Expression and Oncotype Dx Recurrence Score in Estrogen Receptor Positive Breast Carcinomas.

Emmadi R, Canestrari E, Arbieva ZH, Mu W, Dai Y, Frasor J, Wiley E.

PLoS One. 2015 Dec 30;10(12):e0145346. doi: 10.1371/journal.pone.0145346. eCollection 2015.

17.

Dimethyl Fumarate Inhibits the Nuclear Factor κB Pathway in Breast Cancer Cells by Covalent Modification of p65 Protein.

Kastrati I, Siklos MI, Calderon-Gierszal EL, El-Shennawy L, Georgieva G, Thayer EN, Thatcher GR, Frasor J.

J Biol Chem. 2016 Feb 12;291(7):3639-47. doi: 10.1074/jbc.M115.679704. Epub 2015 Dec 18.

18.

A novel aspirin prodrug inhibits NFκB activity and breast cancer stem cell properties.

Kastrati I, Litosh VA, Zhao S, Alvarez M, Thatcher GR, Frasor J.

BMC Cancer. 2015 Nov 4;15:845. doi: 10.1186/s12885-015-1868-7.

19.

NFκB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms.

Frasor J, El-Shennawy L, Stender JD, Kastrati I.

Mol Cell Endocrinol. 2015 Dec 15;418 Pt 3:235-9. doi: 10.1016/j.mce.2014.09.013. Epub 2014 Oct 18. Review.

20.

PHLDA1 expression is controlled by an estrogen receptor-NFκB-miR-181 regulatory loop and is essential for formation of ER+ mammospheres.

Kastrati I, Canestrari E, Frasor J.

Oncogene. 2015 Apr 30;34(18):2309-16. doi: 10.1038/onc.2014.180. Epub 2014 Jun 23.

21.

Growth hormone potentiates 17β-estradiol-dependent breast cancer cell proliferation independently of IGF-I receptor signaling.

Felice DL, El-Shennawy L, Zhao S, Lantvit DL, Shen Q, Unterman TG, Swanson SM, Frasor J.

Endocrinology. 2013 Sep;154(9):3219-27. doi: 10.1210/en.2012-2208. Epub 2013 Jun 19.

22.

14-3-3ζ as a predictor of early time to recurrence and distant metastasis in hormone receptor-positive and -negative breast cancers.

Bergamaschi A, Frasor J, Borgen K, Stanculescu A, Johnson P, Rowland K, Wiley EL, Katzenellenbogen BS.

Breast Cancer Res Treat. 2013 Feb;137(3):689-96. doi: 10.1007/s10549-012-2390-0. Epub 2012 Dec 28.

23.

Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers.

Baumgarten SC, Frasor J.

Mol Endocrinol. 2012 Mar;26(3):360-71. doi: 10.1210/me.2011-1302. Epub 2012 Feb 2. Review.

24.

CBP mediates NF-κB-dependent histone acetylation and estrogen receptor recruitment to an estrogen response element in the BIRC3 promoter.

Pradhan M, Baumgarten SC, Bembinster LA, Frasor J.

Mol Cell Biol. 2012 Jan;32(2):569-75. doi: 10.1128/MCB.05869-11. Epub 2011 Nov 14.

25.

An integrated bioinformatics approach identifies elevated cyclin E2 expression and E2F activity as distinct features of tamoxifen resistant breast tumors.

Huang L, Zhao S, Frasor JM, Dai Y.

PLoS One. 2011;6(7):e22274. doi: 10.1371/journal.pone.0022274. Epub 2011 Jul 15.

26.

The stimulation of HSD17B7 expression by estradiol provides a powerful feed-forward mechanism for estradiol biosynthesis in breast cancer cells.

Shehu A, Albarracin C, Devi YS, Luther K, Halperin J, Le J, Mao J, Duan RW, Frasor J, Gibori G.

Mol Endocrinol. 2011 May;25(5):754-66. doi: 10.1210/me.2010-0261. Epub 2011 Mar 3.

27.

Estrogen promotes breast cancer cell survival in an inhibitor of apoptosis (IAP)-dependent manner.

Stanculescu A, Bembinster LA, Borgen K, Bergamaschi A, Wiley E, Frasor J.

Horm Cancer. 2010 Jun;1(3):127-35. doi: 10.1007/s12672-010-0018-6.

28.

Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NF{kappa}B cooperativity at adjacent response elements.

Pradhan M, Bembinster LA, Baumgarten SC, Frasor J.

J Biol Chem. 2010 Oct 8;285(41):31100-6. doi: 10.1074/jbc.M110.155309. Epub 2010 Aug 12.

29.

Estrogenic and progestagenic effects of extracts of Justicia pectoralis Jacq., an herbal medicine from Costa Rica used for the treatment of menopause and PMS.

Locklear TD, Huang Y, Frasor J, Doyle BJ, Perez A, Gomez-Laurito J, Mahady GB.

Maturitas. 2010 Jul;66(3):315-22. doi: 10.1016/j.maturitas.2010.04.001. Epub 2010 May 7. Erratum in: Maturitas. 2010 Oct;67(2):192.

30.

Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer.

Frasor J, Weaver A, Pradhan M, Dai Y, Miller LD, Lin CY, Stanculescu A.

Cancer Res. 2009 Dec 1;69(23):8918-25. doi: 10.1158/0008-5472.CAN-09-2608. Epub 2009 Nov 17. Erratum in: Cancer Res. 2010 Jan 15;70(2):854. Cancer Res. 2010 Mar 1;70(5):2140.

31.

Estrogenic effects of herbal medicines from Costa Rica used for the management of menopausal symptoms.

Doyle BJ, Frasor J, Bellows LE, Locklear TD, Perez A, Gomez-Laurito J, Mahady GB.

Menopause. 2009 Jul-Aug;16(4):748-55. doi: 10.1097/gme.0b013e3181a4c76a.

32.

Synergistic up-regulation of prostaglandin E synthase expression in breast cancer cells by 17beta-estradiol and proinflammatory cytokines.

Frasor J, Weaver AE, Pradhan M, Mehta K.

Endocrinology. 2008 Dec;149(12):6272-9. doi: 10.1210/en.2008-0352. Epub 2008 Aug 14.

PMID:
18703630
33.

Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene.

Overk CR, Peng KW, Asghodom RT, Kastrati I, Lantvit DD, Qin Z, Frasor J, Bolton JL, Thatcher GR.

ChemMedChem. 2007 Oct;2(10):1520-6.

PMID:
17654759
34.

Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation.

Stender JD, Frasor J, Komm B, Chang KC, Kraus WL, Katzenellenbogen BS.

Mol Endocrinol. 2007 Sep;21(9):2112-23. Epub 2007 Jun 5.

PMID:
17550982
35.

Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome.

Frasor J, Chang EC, Komm B, Lin CY, Vega VB, Liu ET, Miller LD, Smeds J, Bergh J, Katzenellenbogen BS.

Cancer Res. 2006 Jul 15;66(14):7334-40.

36.

Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells.

Chang EC, Frasor J, Komm B, Katzenellenbogen BS.

Endocrinology. 2006 Oct;147(10):4831-42. Epub 2006 Jun 29.

PMID:
16809442
37.

Estrogen down-regulation of the corepressor N-CoR: mechanism and implications for estrogen derepression of N-CoR-regulated genes.

Frasor J, Danes JM, Funk CC, Katzenellenbogen BS.

Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13153-7. Epub 2005 Sep 1.

38.

Distinctive actions of membrane-targeted versus nuclear localized estrogen receptors in breast cancer cells.

Rai D, Frolova A, Frasor J, Carpenter AE, Katzenellenbogen BS.

Mol Endocrinol. 2005 Jun;19(6):1606-17. Epub 2005 Apr 14.

PMID:
15831524
39.

Therapeutic targeting in the estrogen receptor hormonal pathway.

Katzenellenbogen BS, Frasor J.

Semin Oncol. 2004 Feb;31(1 Suppl 3):28-38. Review.

PMID:
15052541
40.

Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) alpha or ERbeta in human osteosarcoma cells: distinct and common target genes for these receptors.

Stossi F, Barnett DH, Frasor J, Komm B, Lyttle CR, Katzenellenbogen BS.

Endocrinology. 2004 Jul;145(7):3473-86. Epub 2004 Mar 19.

PMID:
15033914
41.

Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells.

Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS.

Cancer Res. 2004 Feb 15;64(4):1522-33.

42.

Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype.

Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS.

Endocrinology. 2003 Oct;144(10):4562-74. Epub 2003 Jul 10.

PMID:
12959972
43.

Response-specific and ligand dose-dependent modulation of estrogen receptor (ER) alpha activity by ERbeta in the uterus.

Frasor J, Barnett DH, Danes JM, Hess R, Parlow AF, Katzenellenbogen BS.

Endocrinology. 2003 Jul;144(7):3159-66.

PMID:
12810572
44.

Prolactin regulation of estrogen receptor expression.

Frasor J, Gibori G.

Trends Endocrinol Metab. 2003 Apr;14(3):118-23. Review.

PMID:
12670737
45.

Regulation of nuclear receptor transcriptional activity by a novel DEAD box RNA helicase (DP97).

Rajendran RR, Nye AC, Frasor J, Balsara RD, Martini PG, Katzenellenbogen BS.

J Biol Chem. 2003 Feb 14;278(7):4628-38. Epub 2002 Dec 3.

46.

Differential roles for signal transducers and activators of transcription 5a and 5b in PRL stimulation of ERalpha and ERbeta transcription.

Frasor J, Park K, Byers M, Telleria C, Kitamura T, Yu-Lee LY, Djiane J, Park-Sarge OK, Gibori G.

Mol Endocrinol. 2001 Dec;15(12):2172-81.

PMID:
11731618
48.

Expression of prolactin and its receptor in the baboon uterus during the menstrual cycle and pregnancy.

Frasor J, Gaspar CA, Donnelly KM, Gibori G, Fazleabas AT.

J Clin Endocrinol Metab. 1999 Sep;84(9):3344-50.

PMID:
10487709
49.

Molecular cloning and characterization of the rat ovarian 20 alpha-hydroxysteroid dehydrogenase gene.

Zhong L, Ou J, Barkai U, Mao JF, Frasor J, Gibori G.

Biochem Biophys Res Commun. 1998 Aug 28;249(3):797-803.

PMID:
9731216
50.

The relationship of human granulosa-lutein cell proliferative index to follicular diameter and serum estradiol.

Attaran M, Frasor J, Mascha E, Radwanska E, Rawlins RG.

Obstet Gynecol. 1998 Mar;91(3):449-53.

PMID:
9491876

Supplemental Content

Loading ...
Support Center